OSUR

OraSure is a post-COVID unwind that hasn't found its floor. Revenue has collapsed from $405M (FY2023) to $186M (FY2024) to $115M (FY2025, -38.1% YoY), and the MD&A confirms the culprit is COVID-19 Diagnostics evaporating from $45.1M to $0.62M (-99%). The problem is that the non-COVID base is also eroding, not just the pandemic sugar-high: Diagnostics fell -12% and Sample Management Solutions -25% in 2025. That leaves a business running a -62.6% operating margin, a -$68.7M net loss, and -$49.0M of operating cash burn. Gross margin holding at 41.9% and R&D up +63.3% to $42.5M tell you management is spending hard to rebuild a pipeline rather than harvesting a stable franchise — this is a company in transition, not a steady compounder.

What keeps this from an 'avoid' is the fortress balance sheet. Against a $301M market cap sits $199M cash and only $62.3M total liabilities (0.18x liabilities/equity), so enterprise value is roughly ~$102M on $115M of revenue and $341M of book equity. The stock at $4.35 trades below book value (~$4.93/share) and not far above net cash. At the current ~$49M burn there is multi-year runway, and management is returning capital — a $40M buyback authorized March 2025 with 1.96M shares repurchased in Q4 2025 and shares outstanding already down 7.6% YoY. The downside is genuinely cushioned by cash and hard assets in a way the income statement alone doesn't show.